viewCallitas Health Inc

M Pharmaceutical Inc names new interim boss

Interim CEO Brian Keane told investors he welcomed the chance to assist in the transition of the company.

Former CEO Mathew Lehman resigned last month.

M Pharmaceutical Inc (CNSX:MQ, OTCMKTS:MPHMF) has named Brian Keane as the company’s interim president and chief executive officer.

Keane told investors he welcomed the chance to assist in the transition of the company, and said he looked forward to focussing on the development of its existing technologies whilst also exploring new growth opportunities.

It comes after the resignation of Mathew Lehman and a decision last month to drop plans to acquire a weight loss drug called orlistat. Before that, in December, Martin Mintchev resigned from his position as chief scientific officer.

In a statement to the market, M Pharmaceuticals’ board told investors: "Brian has the requisite knowledge and capital markets experience to execute M Pharma's technology development plan, raise the necessary capital and explore an acquisition strategy while providing leadership to the management team pending the appointment of a full time CEO".

Keane has more than seventeen years of experience in capital markets, investing and corporate consultancy and has been involved in the restructuring of some 75 different companies.

Quick facts: Callitas Health Inc

Price: - CAD

Market: CSE
Market Cap: -

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Callitas Health Inc named herein, including the promotion by the Company of Callitas Health Inc in any Content on the Site, the Company...



M Pharmaceutical boss looking forward to a great 2017 and 2018

Gary Thompson is at the helm of drug company M Pharmaceutical, which he describes as a "small company with big ideas". Talking to Proactive, he said that when finished soon with its acquisition of Cincinnati-based 40 J’s, it will have a current revenue stream from about seven different...

on 8/2/17

2 min read